You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

546 Results
Drug
Other Name(s): Zejula
Mar 2025
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Adjuvant, Palliative
Funding:
Exceptional Access Program
    niraparib - For the maintenance treatment of newly diagnosed or recurrent high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, according to clinical criteria
Mar 2025
Drug
Other Name(s): Caelyx®
Mar 2025
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Funding:
New Drug Funding Program
    Liposomal DOXOrubicin - Single Agent Treatment of Platinum Sensitive Ovarian Fallopian Tube or Primary Peritoneal Cancer
New Drug Funding Program
    Liposomal Doxorubicin - Platinum-Resistant Ovarian Fallopian Tube or Primary Peritoneal Cancer
Mar 2025
Regimen
Cancer Type:
Sarcoma, 
Kaposi's Sarcoma
Intent: Palliative
Funding:
New Drug Funding Program
    Liposomal Doxorubicin - HIV-positive Kaposi's Sarcoma
Mar 2025
Regimen
Intent: Palliative
Mar 2025
Guidelines and Advice
Updated
Mar 2025
Les programmes provinciaux de remboursement des médicaments (PPRM) permettent de financer les médicaments contre le cancer et les services connexes....
The Provincial Drug Reimbursement Programs (PDRP) administers funding programs for cancer drugs and services. These programs help patients access...
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Palliative
Mar 2025

Pages